Hazard ratios with 1-year mortality of ARB use compared with ACEI use after myocardial infarction. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin-II-receptor blocker; CHF, previous diagnosis of congestive heart failure; New Users, no ACEI or ARB use in 365 days before admission for myocardial infarction. ARB, reference group.